Published Online
on April 3, 2006

A more recent version of this article appeared on May 1, 2006

This Article Full Text (PDF) All Versions of this Article: 47/5/874    most recent 01.HYP.0000216794.24161.8cv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McKie, P. M. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by McKie, P. M. Articles by Burnett, J. C., Jr Related Collections Cardio-renal physiology/pathophysiology Risk Factors Epidemiology

Submitted on December 2, 2005
Revised on December 22, 2005

Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide. Biomarker for Mortality in a Large Community-Based Cohort Free of Heart Failure

Paul M. McKie^*; Richard J. Rodeheffer; Alessandro Cataliotti; Fernando L. Martin; Lynn H. Urban; Douglas W. Mahoney; Steven J. Jacobsen; Margaret M. Redfield; and John C. Burnett Jr

From the Cardiorenal Research Laboratory (P.M.M., A.C., F.L.M., M.M.R., J.C.B.), Division of Cardiovascular Diseases (R.J.R., A.C., M.M.R., J.C.B.), and Department of Biostatistics (L.H.U., D.W.M., S.J.J.), Mayo Clinic and Foundation, Rochester, Minn; and Stanley J. Sarnoff Endowment for Cardiovascular Science (P.M.M.), Great Falls, Va.

^* To whom correspondence should be addressed. E-mail: mckie.paul{at}mayo.edu.

Abstract--Recent studies report that, in the absence of heart failure and renal failure, plasma B-type natriuretic peptide (BNP) has prognostic value for mortality. We sought to confirm and extend these previous studies to assess BNP, measured by 3 distinct assays, as a biomarker for mortality in a strategy to enhance efforts at primary prevention and to better understand the clinical phenotype of such subjects at risk. We used a community-based cohort of 2042 subjects from Olmsted County, Minn, and individuals with heart or renal failure were excluded. BNP was assessed using 3 assays including Biosite and Shionogi for mature, biologically active BNP and the Roche assay for apparently nonbiologically active amino-terminal pro-BNP (NT-proBNP). Thorough echocardiographic and clinical data were recorded for all of the participants. Median follow-up for mortality was 5.6 years. BNP by all 3 of the assays was predictive of mortality. NT-proBNP and Biosite assays remained significant even after adjustment for traditional clinical risk factors and echocardiographic abnormalities including left ventricular hypertrophy and diastolic dysfunction. Echocardiography documented widespread structural changes in those with increasing BNP levels yet below levels observed in heart failure. We report in a large, well-characterized community-based cohort, free of heart failure, the first study to compare 3 distinct BNP assays as biomarkers for mortality in the same cohort. Our findings confirm the potential use of NT-proBNP and BNP biomarkers for future events and underscore that these peptides may also serve as biomarkers for underlying cardiac remodeling secondary to diverse cardiovascular disease entities.

Key words: natriuretic peptide • hypertrophy

This article has been cited by other articles:

				G. C.M. Linssen, S. J.L. Bakker, A. A. Voors, R. T. Gansevoort, H. L. Hillege, P. E. de Jong, D. J. van Veldhuisen, R. O.B. Gans, and D. de Zeeuw N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population Eur. Heart J., October 23, 2009; (2009) ehp420v1. [Abstract] [Full Text] [PDF]

				S. C. Palmer, T. G. Yandle, M. G. Nicholls, C. M. Frampton, and A. M. Richards Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma Eur J Heart Fail, September 1, 2009; 11(9): 832 - 839. [Abstract] [Full Text] [PDF]

				R. R.J. van Kimmenade, J. L. Januzzi Jr, J. A. Bakker, A. J. Houben, R. Rennenberg, A. A. Kroon, H. J.G.M. Crijns, M. P. van Dieijen-Visser, P. W. de Leeuw, and Y. M. Pinto Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 884 - 890. [Abstract] [Full Text] [PDF]

				R. Paniagua, D. Amato, S. Mujais, E. Vonesh, A. Ramos, R. Correa-Rotter, and W. H. Horl Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis: Results from the ADEMEX Trial Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 407 - 415. [Abstract] [Full Text] [PDF]

				H. H. Chen, T. M. Sundt, D. J. Cook, D. M. Heublein, and J. C Burnett Jr Low Dose Nesiritide and the Preservation of Renal Function in Patients With Renal Dysfunction Undergoing Cardiopulmonary-Bypass Surgery: A Double-Blind Placebo-Controlled Pilot Study Circulation, September 11, 2007; 116(11_suppl): I-134 - I-138. [Abstract] [Full Text] [PDF]

				C. R. deFilippi, S. L. Seliger, S. Maynard, and R. H. Christenson Impact of Renal Disease on Natriuretic Peptide Testing for Diagnosing Decompensated Heart Failure and Predicting Mortality Clin. Chem., August 1, 2007; 53(8): 1511 - 1519. [Abstract] [Full Text] [PDF]

				W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]

				T. Omland, M. S. Sabatine, K. A. Jablonski, M. M. Rice, J. Hsia, R. Wergeland, S. Landaas, J. L. Rouleau, M. J. Domanski, C. Hall, et al. Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial J. Am. Coll. Cardiol., July 17, 2007; 50(3): 205 - 214. [Abstract] [Full Text] [PDF]

				A. Struthers and C. Lang The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney Eur. Heart J., July 2, 2007; 28(14): 1678 - 1682. [Abstract] [Full Text] [PDF]

				D. M. Heublein, B. K. Huntley, G. Boerrigter, A. Cataliotti, S. M. Sandberg, M. M. Redfield, and J. C. Burnett Jr Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide Hypertension, May 1, 2007; 49(5): 1114 - 1119. [Abstract] [Full Text] [PDF]

				M. A. Konstam Natriuretic Peptides and Cardiovascular Events: More Than a Stretch JAMA, January 10, 2007; 297(2): 212 - 214. [Full Text] [PDF]

				W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2575 - 2583. [Full Text] [PDF]

				R. Becker-Cohen, A. Nir, C. Rinat, S. Feinstein, N. Algur, B. Farber, and Y. Frishberg Risk Factors for Cardiovascular Disease in Children and Young Adults after Renal Transplantation Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1284 - 1292. [Abstract] [Full Text] [PDF]